ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02412787
Recruitment Status : Enrolling by invitation
First Posted : April 9, 2015
Last Update Posted : November 20, 2018
Sponsor:
Information provided by (Responsible Party):
Shire

April 1, 2015
April 9, 2015
November 20, 2018
April 1, 2015
September 1, 2022   (Final data collection date for primary outcome measure)
  • Number of Participants With Adverse Events [ Time Frame: From start of study drug administration up to 121 months ]
    An adverse event is any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in any phase of a clinical study, whether or not considered investigational product-related.
  • Number of Participants With Clinically Significant Changes in Vital Signs, Laboratory Parameters, and 12-lead Electrocardiogram (ECG) Findings [ Time Frame: From start of study drug administration up to 121 months ]
    Number of participants with clinically significant changes will be reported.
  • Maximum Observed Serum Concentration (Cmax) of Idursulfase [ Time Frame: Baseline through Month 121 ]
    The Cmax of Idursulfase will be assessed.
  • Maximum Observed Concentration (Cmax) of Idursulfase in Cerebrospinal Fluid (CSF) [ Time Frame: Baseline through Month 121 ]
    The Cmax of Idursulfase in CSF will be assessed.
  • Change From Baseline in the Concentration of Glycosaminoglycan (GAG) in Cerebrospinal Fluid (CSF) [ Time Frame: Baseline through Month 121 ]
    Concentration of GAG in CSF will be assessed.
  • Change From Baseline in the Concentration of Glycosaminoglycan (GAG) in Urine [ Time Frame: Baseline through Month 121 ]
    Concentration of GAG in urine will be assessed.
  • Number of Participants who Report Anti-idursulfase Antibodies in Cerebrospinal Fluid (CSF) [ Time Frame: From start of study drug administration up to 121 months ]
    The presence of idursulfase-specific antibodies will be assessed.
  • Number of Participants who Report Anti-idursulfase Antibodies in Serum [ Time Frame: From start of study drug administration up to 121 months ]
    The presence of idursulfase-specific antibodies will be assessed.
  • Change in physical and neurological examination to evaluate long-term safety in patients [ Time Frame: Baseline to week 148 ]
  • Change in height and weight [ Time Frame: Baseline to week 148 ]
  • Change in head circumference [ Time Frame: Baseline to week 148 ]
  • Change in auditory capacity for hearing assessment [ Time Frame: Baseline to week 148 ]
  • Number of participants with adverse events as measured by type, severity, and relationship to treatment [ Time Frame: Baseline to week 148 ]
  • Change in vital signs [ Time Frame: Baseline to week 148 ]
  • Change in 12-lead ECG recordings [ Time Frame: Baseline to week 148 ]
  • Change in clinical laboratory testings as measured by serum chemistry, hematology, and urinalysis to evaluate long-term safety in patients [ Time Frame: Baseline to week 148 ]
  • Change in cerebrospinal fluid laboratory standard chemistry to evaluate long-term safety in patients [ Time Frame: Baseline to week 148 ]
  • Change in cerebrospinal fluid laboratory parameters to evaluate long-term safety in patients [ Time Frame: Baseline to week 148 ]
  • Change in anti-idursulfase antibodies in CSF and serum [ Time Frame: Baseline to week 148 ]
  • Change in urine GAG and creatinine [ Time Frame: Baseline to week 148 ]
  • Change in serum albumin [ Time Frame: Baseline to week 148 ]
Complete list of historical versions of study NCT02412787 on ClinicalTrials.gov Archive Site
  • Change From Baseline in Differential Ability Scales, Second Edition (DAS-II) Standard Scores and Standard Cluster Scores [ Time Frame: Baseline through Month 121 ]
    The DAS-II will be used to assess all participants of age 2 years, 6 months or older. The DAS-II comprises 2 overlapping batteries. The Early Years battery is designed for children ages 2 years, 6 months through 6 years, 11 months. The Early Years battery is further divided into the Lower Level for children ages 2 years, 6 months through 3 years, 5 months and Upper Level for children ages 3 years 6 months through 6 years, 11 months. The School Age Battery is designed for children ages 7 years, 0 months through 17 years, 11 months. These batteries are fully co-normed for ages 5 years, 0 months, through 8 years, 11 months. The cluster areas include general conceptual ability (GCA), Verbal, Nonverbal, Spatial, and Special Nonverbal Composite (SNC). The cluster area score represents a score (mean = 100 and standard deviation of 15) on which higher scores indicate a higher level of cognitive ability.
  • Change From Baseline in Age Equivalent Scores of the Bayley Scales of Infant Development, Third Edition (BSID-III) Domains [ Time Frame: Baseline through Month 121 ]
    Participants who are younger than 2 years, 6 months, will be assessed using the BSID-III. The BSID--III is a series of measurements to assess the motor (fine and gross), language (receptive and expressive), and cognitive development of infants and toddlers and consists of a series of developmental play tasks. Raw scores (range 40-160) will be converted to age- equivalent scores to measure ability, skill, and knowledge, expressed as the age at which most individuals reach the same level (age norm; range: 0, unbound).
  • Change From Baseline in Development Quotient (DQ) of the Bayley Scales of Infant Development, Third Edition (BSID-III) Domains [ Time Frame: Baseline through Month 121 ]
    Participants who are younger than 2 years, 6 months, will be assessed using the BSID-III. The BSID--III is a series of measurements to assess the motor (fine and gross), language (receptive and expressive), and cognitive development of infants and toddlers and consists of a series of developmental play tasks. The development quotient (DQ) is a means to express a neurodevelopmental/cognitive delay which will be computed as a ratio and expressed as a percentage using the age equivalent score divided by the age at testing ([age-equivalent score/chronological age] × 100; range: 0-100).
  • Change From Baseline in Standard Scores of the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) Domains [ Time Frame: Baseline through Month 121 ]
    The VABS-II test measures adaptive behaviors, including the ability to cope with environmental changes, to learn new everyday skills, and to demonstrate independence. This test measures the following 4 key domains: communication, daily living skills, socialization, motor skills, and the adaptive behaviour composite (a composite of the other 4 domains). The standard scores represent a score (mean = 100 and standard deviation of 15) on which higher scores indicate a higher level of cognitive ability.
  • Change From Baseline in Standard Composite Scores of the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) Domains [ Time Frame: Baseline through Month 121 ]
    The VABS-II test measures adaptive behaviors, including the ability to cope with environmental changes, to learn new everyday skills, and to demonstrate independence. This test measures the following 4 key domains: communication, daily living skills, socialization, motor skills, and the adaptive behavior composite (a composite of the other 4 domains). The ABC score ranges from 20 to 160 on which higher scores indicate a higher level of adaptive functioning. A positive change value indicates improvement in adaptive functioning.
  • Change From Baseline in Age Equivalents Score of the Differential Ability Scales, Second Edition (DAS-II) [ Time Frame: Baseline through Month 121 ]
    DAS-II will be used to assess all participants of age 2 years (Y), 6 months (M) or older. DAS-II comprises 2 overlapping batteries. Early Years Battery (EYB) is designed for ages 2Y,6M-6Y,11M. School Age Battery is designed for ages 7Y,0M-17Y,11M. These batteries are fully co-normed for age 5Y,0M-8Y,11M. Core subtests include Verbal (V) Comprehension, Picture Similarities, Naming Vocabulary, Pattern Construction (PC), Matrices (M) and Copying for DAS-II Early Y and Recall of Designs, Word Definitions, PC, M, Verbal Similarities, and Sequential and Quantitative Reasoning for DAS-II School Years. Standardized scores will be converted to age equivalent scores (AES) to measure ability, skill, and knowledge expressed as age at which most individuals reach same level. Mean AES will be obtained by averaging out AES. Higher score (HS) indicates greater cognitive ability (CA). Subtests score represent a score (mean=50 and standard deviation of 10) on which HS indicate a higher level of CA.
  • Change From Baseline in Developmental Quotients (DQ) of the Differential Ability Scales, Second Edition (DAS-II) [ Time Frame: Baseline through Month 121 ]
    The DAS-II will be used to assess all participants of age 2 years (Y), 6 months (M) or older. The DAS-II comprises 2 overlapping batteries. The Early Years battery (EYB) is designed for children ages (CA) 2Y, 6M, through 6Y, 11M. The EYB is further divided into the Lower Level for CA 2Y, 6M through 3Y, 5M and Upper Level for CA 3Y, 6M through 6Y, 11M. The School Age Battery is designed for CA 7Y, 0M through 17Y, 1M. These batteries are fully co-normed for ages 5Y, 0M, through 8Y, 11M. The core subtests include Verbal Comprehension, Picture Similarities, Naming Vocabulary, Pattern Construction, Matrices, and Copying for the DAS-II Early Y and Recall of Designs, Word Definitions, Pattern Construction, Matrices, Verbal Similarities, and Sequential and Quantitative Reasoning for the DAS-II School Y. The DQ will be computed as a ratio and expressed as a percentage using the age equivalent score (AES) divided by the age at testing ([AES/chronological age] × 100; range, 0-100).
  • Change From Baseline in T-scores of the Core Subtests Differential Ability Scales, Second Edition (DAS-II) [ Time Frame: Baseline through Month 121 ]
    The DAS-II will be used to assess all participants of age 2 years (Y), 6 months (M) or older. The DAS-II comprises 2 overlapping batteries. The Early Years battery (EYB) is designed for children ages (CA) 2Y, 6M, through 6Y, 11M. The EYB is further divided into the Lower Level for CA 2Y, 6M through 3Y, 5M and Upper Level for CA 3Y, 6M through 6Y, 11M. The School Age Battery is designed for CA 7Y, 0M through 17Y, 11M. These batteries are fully co-normed for ages 5Y, 0M, through 8Y, 11M. The core subtests (CS) include Verbal Comprehension, Picture Similarities, Naming Vocabulary, Pattern Construction, Matrices, and Copying for the DAS-II Early Years and Recall of Designs, Word Definitions, Pattern Construction, Matrices, Verbal Similarities, and Sequential and Quantitative Reasoning for the DAS-II School Years. The CS score represent a score (mean = 50 and standard deviation of 10) on which higher scores indicate a higher level of cognitive ability.
  • Change From Baseline in Age Equivalents Score of the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) Sub Domains [ Time Frame: Baseline through Month 121 ]
    The VABS-II test measures adaptive behaviors, including the ability to cope with environmental changes, to learn new everyday skills, and to demonstrate independence. This test measures the following subdomains of 5 key domains: Communication (Receptive, Expressive, Written), Daily Living Skills (Personal, Domestic, Community), Socialization (Interpersonal Relationships, Play and Leisure Time, Coping Skills), Motor Skills (Gross, Fine). The mean age equivalent score will be obtained by averaging out the age-equivalent scores for the all the sub-domains except for Gross and Fine motor skills (range: 0, unbound).
  • Change From Baseline in Developmental Quotients (DQ) of the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) Sub Domains [ Time Frame: Baseline through Month 121 ]
    The VABS-II test measures adaptive behaviors, including the ability to cope with environmental changes, to learn new everyday skills, and to demonstrate independence. This test measures the following subdomains of 5 key domains: Communication (Receptive, Expressive, Written), Daily Living Skills (Personal, Domestic, Community), Socialization (Interpersonal Relationships, Play and Leisure Time, Coping Skills), Motor Skills (Gross, Fine). The DQ will be computed as a ratio and expressed as a percentage using the age-equivalent score divided by the age at testing ([age-equivalent score/chronological age] × 100; range, 0-100).
  • Change From Baseline in v-Scores of the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) Sub Domains [ Time Frame: Baseline through Month 121 ]
    The VABS-II test measures adaptive behaviors, including the ability to cope with environmental changes, to learn new everyday skills, and to demonstrate independence. This test measures the following subdomains of 5 key domains: Communication (Receptive, Expressive, Written), Daily Living Skills (Personal, Domestic, Community), Socialization (Interpersonal Relationships, Play and Leisure Time, Coping Skills), Motor Skills (Gross, Fine). The V-scale scores represent a score (mean = 15 and standard deviation of 3; range: 1-24) on which higher scores indicate a higher level of adaptive functioning.
  • Change From Baseline in v-Scale Scores of the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) Maladaptive Behavior Index and its Subscales [ Time Frame: Baseline through Month 121 ]
    The VABS-II test measures adaptive behaviors, including the ability to cope with environmental changes, to learn new everyday skills, and to demonstrate independence. Maladaptive behavior index is a composite of the internalizing, externalizing, and other types of undesirable behavior that may interfere with the individual's adaptive functioning. The v-Scale scores represent a score (mean = 15 and standard deviation of 3; range: 1-24) on which higher scores indicate a higher level of adaptive functioning.
  • Change From Baseline in Observed Maladaptive Levels of the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) Maladaptive Behavior Index and its Subscales [ Time Frame: Baseline through Month 121 ]
    The VABS-II test measures adaptive behaviors, including the ability to cope with environmental changes, to learn new everyday skills, and to demonstrate independence. Maladaptive behavior index is a composite of the internalizing, externalizing, and other types of undesirable behavior that may interfere with the individual's adaptive functioning. The V scale scores represent a score (mean = 15 and standard deviation of 3; range: 1-24) on which higher scores indicate a higher level of cognitive ability.
  • Change From Baseline in Brain Structure Volume as Measured by Magnetic Resonance Imaging (MRI) [ Time Frame: Baseline through Month 121 ]
    Brain structure volume will be assessed from brain total intracranial volume, brain total tissue volume, brain total white matter, brain total gray matter, and total CSF volume as measured by MRI.
  • Change in standard scores in cluster areas of the DAS-II / BAS-II [ Time Frame: Baseline to week 148 ]
  • Change in standard scores of the VABS-II domains [ Time Frame: Baseline to week148 ]
  • Change in T-scores for the subtests of the DAS-II [ Time Frame: Baseline to week 148 ]
  • Change in V-scale scores of the VABS-II subdomains [ Time Frame: Baseline to week 148 ]
  • Change in observed maladaptive levels of the VABS-II Maladaptive Behavior Index and its subscales [ Time Frame: Baseline to week 148 ]
  • Change in brain structure volume as measured by magnetic resonance imagine (MRI) [ Time Frame: Baseline to week 148 ]
Not Provided
Not Provided
 
Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094
An Open Label Extension of Study HGT-HIT-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction With Elaprase® in Patients With Hunter Syndrome and Cognitive Impairment
This extension study will allow participants that completed Study HGT-HIT-094 to continue receiving Elaprase treatment in conjunction with idursulfase IT or to continue receiving Elaprase treatment and begin concurrent IT treatment for those that did not receive idursulfase IT treatment in Study HGT-HIT-094.
Not Provided
Interventional
Phase 2
Phase 3
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Hunter Syndrome
  • Drug: Idursulfase-IT
    Participants will receive 10 mg of idursulfase-IT intrathecally via IDDD or LP once every 28 days. Participants who are younger than 3 years of age will receive an adjusted dose of 7.5 mg (>8 months to 30 months of age) and 10 mg (>30 months to 3 years of age).
    Other Name: HGT-2310
  • Drug: Elaprase
    Participants will receive intravenous (IV) Elaprase infusions at a minimum of 48 hours after IT administration of idursulfase-IT.
Experimental: Idursulfase-IT
Participants will receive 10 milligrams (mg) of idursulfase-IT intrathecally via intrathecal drug delivery device (IDDD) or lumbar puncture (LP) once every 28 days along with standard-of-care therapy with Elaprase for 480 weeks. Participants who are younger than 3 years of age will receive an adjusted dose of 7.5 mg (greater than [>] 8 months to 30 months of age) and 10 mg (>30 months to 3 years of age) of idursulfase-IT.
Interventions:
  • Drug: Idursulfase-IT
  • Drug: Elaprase
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Enrolling by invitation
49
42
September 1, 2022
September 1, 2022   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Participants must have completed Visit Week 52 assessments in Study HGT-HIT-094 (NCT02055118).
  • The participant's parent(s) or legally authorized guardian(s) must have voluntarily signed an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved informed consent form after all relevant aspects of the study have been explained and discussed. Consent of the participant's parent(s) or legally authorized guardian(s) and the participant's consent/assent, as relevant, must be obtained.
  • The participant has continued to receive Elaprase on a regular basis in Study HGT-HIT-094 (NCT02055118).

Exclusion Criteria:

  • The participant has experienced, in the opinion of the investigator, a safety or medical issue that contraindicates treatment with idursulfase-IT, including, but not limited to, uncontrolled seizure disorder, bleeding disorder, and clinically relevant hypertension.
  • The participant has a known hypersensitivity to any of the components of idursulfase-IT.
  • The participant has clinically relevant intracranial hypertension.
  • The participant is enrolled in another clinical study, other than HGT-HIT-094 (NCT02055118), that involves clinical investigations or use of any investigational product (drug or [intrathecal/spinal] device) within 30 days prior to study enrollment or at any time during the study.
  • The participant has any known or suspected hypersensitivity to anesthesia or is thought to be at an unacceptably high risk for anesthesia due to compromised airways or other conditions.
  • The participant has a condition that is contraindicated as described in the SOPH-A-PORT® Mini S, Implantable Access Port, Spinal, Mini Unattached, with Guidewire (SOPH-A-PORT Mini S) intrathecal drug delivery device (IDDD) Instructions for Use, including:

    1. The participant has had, or may have, an allergic reaction to the materials of construction of the SOPH-A-PORT Mini S device.
    2. The participant's body size is too small to support the size of the SOPH-A-PORT Mini S Access Port, as judged by the investigator.
    3. The participant's drug therapy requires substances known to be incompatible with the materials of construction.
    4. The participant has a known or suspected local or general infection.
    5. The participant is at risk of abnormal bleeding due to a medical condition or therapy.
    6. The participant has 1 or more spinal abnormalities that could complicate safe implantation or fixation.
    7. The participant has a functioning CSF shunt device.
    8. The participant has shown an intolerance to an implanted device.
Sexes Eligible for Study: Male
Gender Based Eligibility: Yes
up to 18 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
Australia,   Canada,   France,   Mexico,   Spain,   United Kingdom,   United States
Argentina,   Colombia
 
NCT02412787
SHP609-302
2014-004143-13 ( EudraCT Number )
Yes
Not Provided
Plan to Share IPD: No
Shire
Shire
Not Provided
Study Director: Study Director Shire
Shire
November 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP